2006
Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer
Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP. Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer. JAMA 2006, 295: 1658-1667. PMID: 16609087, PMCID: PMC1459540, DOI: 10.1001/jama.295.14.1658.Peer-Reviewed Original ResearchConceptsER-positive tumorsER-positive patientsEstrogen receptor statusAdjuvant chemotherapyOverall survivalBreast cancerBreast cancer estrogen receptor statusNode-positive breast cancer patientsNode-positive breast cancerER-negative breast cancerDoxorubicin/cyclophosphamideRegimens of cyclophosphamideER-negative patientsLeukemia Group BLow-dose cyclophosphamideNode-positive tumorsBreast cancer patientsRate of recurrenceRelative risk reductionER-negative tumorsMortality rate reductionAdjuvant treatmentEndocrine therapyER statusRandomized trials
2005
Optimizing Adjuvant Endocrine Therapy in Postmenopausal Women With Early-Stage Breast Cancer: A Decision Analysis
Punglia RS, Kuntz KM, Winer EP, Weeks JC, Burstein HJ. Optimizing Adjuvant Endocrine Therapy in Postmenopausal Women With Early-Stage Breast Cancer: A Decision Analysis. Journal Of Clinical Oncology 2005, 23: 5178-5187. PMID: 15998905, DOI: 10.1200/jco.2005.02.964.Peer-Reviewed Original ResearchConceptsDisease-free survivalDisease-free survival estimatesAromatase inhibitor monotherapyYears of tamoxifenAromatase inhibitorsSequential therapyBreast cancerInhibitor monotherapyPostmenopausal womenTreatment strategiesHormone receptor-positive breast cancerDisease-free survival ratesDistant disease-free survivalReceptor-positive breast cancerEarly-stage breast cancerSurvival estimatesAdjuvant endocrine therapyAromatase inhibitor therapyCross-over treatmentNode-positive patientsSequential adjuvant therapyPostmenopausal breast cancerRelative risk reductionRandomized clinical trialsSequential treatment strategy